Core Insights - Cue Biopharma announces the appointment of Daniel Baker, M.D., as interim chief development officer (CDO) effective November 25, 2024, while Anish Suri, Ph.D., transitions to principal research and immunology advisor [1][2] - The organizational changes aim to enhance the company's growth and focus on advancing its drug pipeline in oncology and autoimmunity [2][3] Company Overview - Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics designed to selectively engage and modulate disease-specific T cells for cancer and autoimmune disease treatment [1][5] - The company's proprietary platform, Immuno-STAT™, aims to harness the body's immune system without broad systemic immune modulation [5] Leadership Experience - Dr. Daniel Baker brings over 20 years of drug development experience, including significant roles at Johnson & Johnson, where he oversaw numerous Phase I-III trials leading to over 15 regulatory approvals [2][3] - Dr. Baker's previous positions include CEO and founder of Kira Therapeutics and Executive Director at Galapagos Therapeutics [2] Strategic Focus - The company aims to leverage Dr. Baker's expertise in immunotherapeutics to enhance clinical development and registrational strategies [3][4] - The transition is expected to strengthen the company's mission to deliver novel immunotherapies to patients [3]
Cue Biopharma Announces Strategic Organizational Transition